Penn/VA center for studies of addiction

Neuropharmacology

Volumn 56, Issue SUPPL. 1, 2009, Pages 44-47

  O'Brien, Charles P ^a   McLellan, A Thomas ^b   Childress, Anna Rose ^a   Woody, George E ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b TREATMENT RESEARCH INSTITUTE   (United States)

Author keywords

Alcohol and other drugs; Brain changes; Chronic disease; Conditioning; Randomized clinical trials

Indexed keywords

ALCOHOL; AMANTADINE; BUPRENORPHINE; COCAINE; CYCLAZOCINE; DIAMORPHINE; METHADONE; MODAFINIL; NALOXONE; NALTREXONE; OPIATE; PROPRANOLOL; TOPIRAMATE;

ALCOHOL ABUSE; ALCOHOLISM; ANXIETY DISORDER; BIPOLAR DISORDER; CLINICAL PRACTICE; COCAINE DEPENDENCE; DEPRESSION; DISEASE SEVERITY; DRUG DEPENDENCE; DRUG DEPENDENCE TREATMENT; EVIDENCE BASED MEDICINE; HUMAN; MENTAL HEALTH CARE; OPIATE ADDICTION; PRIORITY JOURNAL; PSYCHIATRIST; PSYCHOLOGIST; REVIEW; SCHIZOPHRENIA; SOCIAL WORKER; SUBSTANCE ABUSE; UNITED STATES; VETERAN;

BIOMEDICAL RESEARCH; HOSPITALS, VETERANS; HUMANS; PENNSYLVANIA; SUBSTANCE-RELATED DISORDERS;

EID: 58049179528     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2008.06.030     Document Type: Review

References (38)

1. Altshuler H.L., Phillips P.A., and Feinhandler D.A. Alteration of ethanol self-administration by naltrexone. Life Sci. 26 (1980) 679-688
2. Anton R.F., Oroszi G., O'Malley S., Couper D., Swift R., Pettinati H., and Goldman D. An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch. Gen. Psychiatry 65 (2008) 135-144
3. Arndt I.O., Dorozynsky L., Woody G.E., McLellan A.T., and O'Brien C.P. Desipramine treatment of cocaine dependence in methadone-maintained patients. Arch. Gen. Psychiatry 49 (1992) 888-893
4. Childress A.R., Ehrman R.N., Wang Z., Li Y., Sciortino N., Hakun J., Jens W., Suh J., Listerud J., Marquez K., Franklin T., Langleben D., Detre J., and O'Brien C.P. Prelude to passion: limbic activation by "unseen" drug and sexual cues. PLoS ONE 3 (2008) e1506
5. Childress A.R., Mozley P.D., McElgin W., Fitzgerald J., Reivich M., and O'Brien C.P. Limbic activation during cue-induced cocaine craving. Am. J. Psychiatry 156 1 (1999) 11-18
6. Cornish J.W., Metzger D., Woody G.E., Wilson D., McLellan A.T., Vandergrift B., and O'Brien C.P. Naltrexone pharmacotherapy for opioid dependent federal probationers. J. Subst. Abuse Treat. 14 (1997) 529-534
7. Dackis C., and O'Brien C. Glutamatergic agents for cocaine dependence. Ann. N. Y. Acad. Sci. 1003 (2003) 328-345
8. Dackis C.A., Lynch K.G., Yu E., Samaha F.F., Kampman K.M., Cornish J.W., Rowan A., Poole S., White L., and O'Brien C.P. Modafinil and cocaine: a double-blind, placebo-controlled drug interaction study. Drug Alcohol Depend. 70 (2003) 29-37
9. Franklin T.R., Wang Z., Wang J., Sciortino N., Harper D., Li Y., Ehrman R., Kampman K., O'Brien C.P., Detre J.A., and Childress A.R. Limbic activation to cigarette smoking cues independent of nicotine withdrawal: a perfusion fMRI study. Neuropsychopharmacology 32 (2007) 2301-2309
10. Fudala P.J., Yu E., Macfadden W., Boardman C., and Chiang C.N. Effects of buprenorphine and naloxone in morphine-stabilized opioid addicts. Drug Alcohol Depend. 50 (1998) 1-8
11. Gawin F.H., Kleber H.D., Byck R., Rounsaville B.J., Kosten T.R., Jatlow P.I., and Morgan C. Desipramine facilitation of initial cocaine abstinence. Arch. Gen. Psychiatry 46 (1989) 117-121
12. Gianoulakis C., Krishnan B., and Thavundayil J. Enhanced sensitivity of pituitary β-endorphin to ethanol in subjects at high risk of alcoholism. Arch. Gen. Psychiatry 53 (1996) 250-257
13. Goldberg S.R., and Schuster C.R. Conditioned morphine-induced abstinence changes: persistence in post morphine-dependent monkeys. J. Exp. Anal. Behav. 14 (1970) 33-46
14. Hart C., Haney M., Vosburg S., Rubin E., and Foltin R.W. Smoked cocaine self-administration is decreased by modafinil. Neuropsychopharmacology 33 (2008) 761-768
15. King A., Volpicelli J., Frazer A., and O'Brien C. Effect of naltrexone on subjective alcohol response in subjects at high and low risk for future alcohol dependence. Psychopharmacology 129 (1997) 15-22
16. Krupitsky E.M., Zvartau E.E., Masalov D.V., Tsoi M.V., Burakov A.M., Egorova V.Y., Didenko T.Y., Romanova T.N., Ivanova E.B., Bespalov A.Y., Verbitskaya E.V., Neznanov N.G., Grinenko A.Y., O'Brien C.P., and Woody G.E. Naltrexone for heroin dependence treatment in Russia. J. Subst. Abuse Treat. 26 4 (2004) 285-294
17. Krupitsky E.M., Zvartau E.E., Masalov D.V., Tsoi M.V., Burakov A.M., Egorova V.Y., Didenko T.Y., Romanova T.N., Ivanova E.B., Bespalov A.Y., Verbitskaya E.V., Neznanov E.G., Grinenko A.Y., O'Brien C.P., and Woody G.E. Naltrexone and fluoxetine for heroin dependence treatment in St. Petersburg, Russia. J. Subst. Abuse Treat. 31 (2006) 319-328
18. Malcolm R., Swayngim K., Donovan J.L., DeVane C.L., Elkashef A., Chiang N., Khan R., Mojsiak J., Myrick D.L., Hedden S., Cochran K., and Woolson R.F. Modafinil and cocaine interactions. Am. J. Drug Alcohol Abuse 32 (2006) 577-587
19. Marlowe D.B., Festinger D.S., Dugosh K.L., and Lee P.A. Are judicial status hearings a "key component" of drug court? Six and twelve months outcomes. Drug Alcohol Depend. 79 (2005) 145-155
20. McLellan A.T., Alterman A.I., Cacciola J., Metzger D., and O'Brien C.P. A new measure of substance abuse treatment: initial studies of the treatment services review. J. Nerv. Ment. Dis. 180 2 (1992) 101-110
21. McLellan A.T., Grissom G.R., Zanis D., Randall M., Brill P., and O'Brien C.P. Problem-service 'matching' in addiction treatment. A prospective study in 4 programs. Arch. Gen. Psychiatry 54 (1997) 730-735
22. McLellan A.T., Luborsky L., Woody G.E., and O'Brien C.P. An improved diagnostic evaluation instrument for substance abuse patients: the addiction severity index. J. Nerv. Ment. Dis. 168 (1980) 26-33
23. McLellan A.T., Luborsky L., Woody G.E., O'Brien C.P., and Druley K.A. Predicting response to alcohol and drug abuse treatments. Role of psychiatric severity. Arch. Gen. Psychiatry 40 (1983) 620-625
24. Metzger D.S., Navaline H., and Woody G.E. Drug abuse treatment as AIDS prevention. Public Health Rep. 113 Suppl. 1 (1998) 97-106
25. Metzger D.S., Woody G.E., McLellan A.T., O'Brien C.P., Druley P., Navaline H., DePhilippis D., Stolley P., and Abrutyn E. Human immunodeficiency virus seroconversion among intravenous drug users in- and out-of-treatment: an 18-month prospective follow-up. J. Acquir. Immune Defic. Syndr. 6 9 (1993) 1049-1056
26. Monterosso J.R., Flannery B.A., Pettinati H.M., Oslin D.W., Rukstalis M., O'Brien C.P., and Volpicelli J.R. Predicting treatment response to naltrexone: the influence of craving and family history. Am. J. Addict. 10 (2001) 258-268
27. O'Brien C.P. Prospects for a genomic approach to the treatment of alcoholism. Arch. Gen. Psychiatry 65 (2008) 132-133
28. O'Brien C.P., Testa T., O'Brien T.J., Brady J.P., and Wells B. Conditioned narcotic withdrawal in humans. Science 195 (1977) 1000-1002
29. O'Brien C.P., Woody G.E., and McLellan A.T. A new tool in the treatment of impaired physicians. Phila. Med. 82 (1986) 442-446
30. O'Malley S.S., Jaffe A.J., Chang G., Schottenfeld R.S., Meyer R.E., and Rounsaville B. Naltrexone and coping skills therapy for alcohol dependence: a controlled study. Arch. Gen. Psychiatry 49 (1992) 881-887
31. Oslin D.W., Berrettini W., Kranzler H.R., Pettinati H., Gelernter J., Volpicelli J.R., and O'Brien C.P. A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology 28 (2003) 1546-1552
32. Pechansky F., von Diemen L., Kessler F., Hirakata V., Metzger D., and Woody G.E. Preliminary estimates of HIV prevalence and incidence among cocaine abusers of Porto Alegre, Brazil. J. Urban Health 80 1 (2003) 115-126
33. Volkow N.D., Wang G.J., Telang F., Fowler J.S., Logan J., Childress A.R., Jayne M., Ma Y., and Wong C. Cocaine cues and dopamine in dorsal striatum: mechanism of craving in cocaine addiction. J. Neurosci. 26 (2006) 6583-6588
34. Volpicelli J.R., Alterman A.I., Hayashida M., and O'Brien C.P. Naltrexone in the treatment of alcohol dependence. Arch. Gen. Psychiatry 49 (1992) 876-880
35. Volpicelli J.R., O'Brien C.P., Alterman A.I., and Hayashida M. Naltrexone and the treatment of alcohol dependence: initial observations. In: Reid L.B. (Ed). Opioids, Bulimia, Alcohol Abuse and Alcoholism (1990), Springer-Verlag, New York 195-214
36. Woody G.E., Luborsky L., McLellan A.T., O'Brien C.P., Beck A.T., Blaine J., Herman I., and Hole A. Psychotherapy for opiate addicts. Does it help?. Arch. Gen. Psychiatry 40 (1983) 639-645
37. Woody G.E., McLellan A.T., Luborsky L., and O'Brien C.P. Psychotherapy in community methadone programs: a validation study. Am. J. Psychiatry 152 (1995) 1302-1308
38. Woody G.E., Metzger D., Navaline H., McLellan T., and O'Brien C.P. Psychiatric symptoms, risky behavior, and HIV infection. NIDA Res. Monogr 172 (1997) 156-170